Compare Biogen Inc (BIIB) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Docusign Inc — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while Docusign Inc trades at $58.39 (market cap $11.33B). The key difference: Biogen Inc is far larger — about 2.7× Docusign Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | DOCU | |
|---|---|---|
Market Cap | $30.13B | $11.33B |
Sector | Health | Technology |
52-Week High | $216.63 | $85.01 |
52-Week Low | $128.93 | $41.75 |
Enterprise Value | $37.20B | $10.70B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
